Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of April 2022
Date of Report: April 5, 2022
Principal Executive Office: 117 Avenue de Luminy, 13009 Marseille, France
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K serves as a cover document for a press release (Exhibit 99.1) and does not contain embedded financial statements or numerical data.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. The document references a press release dated April 5, 2022, but the content of that release is not included in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. No narrative discussion or forward-looking statements are present in the cover document itself.
Investor Verification Checklist
- Review the full text of the Press Release dated April 5, 2022 (Exhibit 99.1) referenced in this filing to understand the specific corporate event or announcement.
- Verify the company's current cash position and burn rate in the most recent Form 20-F or quarterly report, as this 6-K contains no financial data.
- Confirm the status of clinical trials or regulatory milestones that likely prompted this specific April 2022 announcement.